ResVita Bio, a therapeutics company focused on treatments for skin diseases, today announced that the FDA awarded the Orphan Drug Designation to RVB-003 for the treatment of Netherton Syndrome, a ...

As healthcare rapidly evolves, the demand for visionary leaders has never been greater. The ongoing shortage of healthcare professionals, combined with recent changes in policy, governance, and ...